According to Future Market Insights (FMI), the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market sales was valued at around US$ 3.9 billion in 2022 and is predicted to reach US$ 5.5 billion by 2030.
Sepsis, toxic shock syndrome, bacteremia, osteomyelitis, endocarditis, meningitis, pneumonia are amongst the life-threatening diseases caused by Staphylococcus Aureus bacteria. These diseases are cured by antibiotics.
Some form of staphylococcus aureus that has developed resistance to a broad range of antibiotics fall in the category of “Methicillin-Resistant Staphylococcus Aureus (MRSA)”. This resistance is one of the key factors driving the market in the near future as well as extensive research ought to be on the anvil to devise new medications.
According to FMI’s latest study, the rising incidences of MRSA all over the world are likely to create demand for safe and efficient drugs during the forecast period.
Request a report sample to gain comprehensive insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10406
Key Takeaways of MRSA Treatment Market Study
- In terms of drug class, glycopeptides (vancomycin) and oxazolidinones (linezolid) are collectively expected to account for over 75% of revenue share in the MRSA treatment market owing to preference of both antibiotic classes as a first-line treatment against MRSA infections and used in more than 80% of MRSA cases treatment.
- By route of administration, intravenous (IV) route of administration remains the recommended option. Drugs that can be administered through IV are likely to gain more than one-half of market share in the MRSA treatment market during the forecast period.
- By indication, skin and soft tissue infections (SSTIs) are leading the market and expected to gain more than 40% of revenue share followed by the pneumonia over the forecast period.
- Incidence of healthcare acquired MRSA is higher than community acquired MRSA, and FMI opines status-quo to remain unchanged during the assessment period
- North America is the highest revenue generating market by region due to high incidence of MRSA infections
- Asia Pacific is expected to witness high demand for MRSA testing systems due to high incidences of MRSA infection herein. For example – Journal of Family Medicine and Primary Care, in 2021, stated that occurrence of MRSA among kids aged 5 to 15 is between 16 and 52%. India alone accounts for 4-19% of these infections.
Government and Pharma Industry Focus on Working in Unison to Develop Advanced Treate
As per University of Melbourne’s researchers, “Teixobactin” responds positively against MRSA. These results are likely to pave the way for development of antibacterial drugs to treat multi-drug resistant Gram-positive infections with thick cell wall. This will open wider doors for MRSA treatment market all over Australia and the other countries in Asia-Pacific. Teixobactin is already known for destroying Mycobacterium tuberculosis.
Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you@ https://www.futuremarketinsights.com/ask-question/rep-gb-10406
Competitive Landscape
Companies in the Methicillin-Resistant Staphylococcus Aureus (MRSA) treatment industry are moderately competitive, with numerous players present. These players are part of several strategic alliances. The product launch and acquisition speed up the manufacturer’s strategy to capitalise on market share and gain a sizable market share. Some of the recent instances include:
- Melinta Therapeutics will commercialise KIMYRSA, a lipoglycopeptide antibiotic that provides a complete course of therapy for acute bacterial skin and skin structure infections, in July 2021. On March 12, 2021, the FDA approved KIMYRSA for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus.
- Wockhardt stated in January 2020 that two novel antibiotics, EMROK (IV) and EMROK O (Oral), had received regulatory approval for acute bacterial skin and skin structure infections, including diabetic foot infections and concomitant bacteremia. The new medicine will target superbugs such as Methicillin-resistant Staphylococcus aureus (MRSA), a key cause of antibiotic resistance.
Key Players
- Pfizer Inc.
- Allergan Plc.
- Johnsons & Johnson
- Colgate-Palmolive Company
- The Procter & Gamble
- Merck & Co., Inc.
- Baxter Healthcare Corporation
- Fresenius Kabi LLC
- Sandoz Inc
- Others
Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/10406
Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market By Category
By Drug Class:
- Glycopeptides
- Vancomycin
- Oxazolidinones
- Linezolid
- Lipopeptides
- Daptomycin
- Antiseptics
- Chlorhexidine
- Cetylpyridinium Chloride
- Hydrogen Peroxide
- Phenols
- Lipoglycopeptides
- Dalbavancin
- Telavancin
- Oritavancin
- Glycylcycline
- Tigecycline
- Streptogramins
- Quinupristin
- Dalfopristin
- Naturals/Herbals
- Tetracycline
- Doxycycline
- Minocycline
- Lincomycin
- Clindamycin
- Others
By Indication:
- Skin and Soft Tissue Infections (SSTIs)
- Pneumonia
- Bloodstream Infections
- Surgical and Medical Infections
- Others
By Route of Administration:
- Intravenous
- Oral
- Topical
- Nasal
- Cutaneous
- Intramuscular
By Type of MSRA:
- Healthcare Acquired MRSA
- Community Acquired MRSA
- Hospital Acquired MRSA
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
